Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Oncocyte Corporation is a precision diagnostics company with a mission to improve patient outcomes by providing clear insights to physicians and payors. The company focuses on developing and commercializing proprietary laboratory developed tests (LDTs) that accelerate and optimize cancer diagnosis and treatment. Oncocyte's key products include VitaGraft™, for transplant rejection monitoring, and DetermaIO™, a gene expression test that predicts patient response to immunotherapy.
The Irvine headquarters serves as the primary center for corporate administration, strategic operations, research and development leadership, and commercial activities.
Located within a modern business park, the facility likely includes advanced laboratory spaces for R&D and office areas designed to support a biotech company's operational needs.
Oncocyte likely fosters a dynamic and innovative work culture, emphasizing scientific rigor, collaboration, and a strong focus on improving patient lives through advanced cancer diagnostics.
Its location in Irvine's prominent life sciences cluster offers strategic advantages, including access to a skilled talent pool, research institutions, and a supportive ecosystem for biotech development and commercialization.
While Oncocyte's primary operations, including its headquarters and main laboratory, are based in the United States, the company's ambition is to make its precision diagnostic tests available to patients and clinicians globally. This may involve strategic partnerships, distribution agreements, and seeking regulatory approvals in various international markets to extend the reach of its innovative cancer diagnostic solutions.
15 Cushing
Irvine
CA
USA
Address: 2705 Transworld Dr, Nashville, TN 37217
Serves as a key operational hub for the company's diagnostic testing services, supporting clinical sample analysis and the delivery of actionable results to physicians.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Oncocyte Corporation' leadership includes:
Oncocyte Corporation has been backed by several prominent investors over the years, including:
In the past year, Oncocyte Corporation has experienced key leadership transitions, including the appointment of a new CEO and a new CFO, to steer the company's strategic growth in the precision oncology space.
Discover the tools Oncocyte Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Oncocyte Corporation likely utilizes common corporate email address patterns. A frequent format is the first initial followed by the last name. Alternative formats could include 'first.last'.
[first_initial][last]@oncocyte.com
Format
jriggs@oncocyte.com
Example
75%
Success rate
GlobeNewswire • May 15, 2024
Oncocyte Corporation announced its Q1 2024 financial results, detailing revenue from its VitaGraft transplant monitoring tests and advancements with its DetermaIO immunotherapy response test. The company also provided updates on strategic initiatives and financial outlook....more
GlobeNewswire • April 2, 2024
A peer-reviewed publication validated DetermaIO™'s ability to predict immunotherapy benefits in metastatic triple-negative breast cancer patients, underscoring its clinical utility....more
GlobeNewswire • March 18, 2024
Oncocyte Corporation announced the appointment of Andrea (Andi) James as its new Chief Financial Officer, effective March 18, 2024. Ms. James brings significant financial leadership experience from the life sciences sector....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Oncocyte Corporation, are just a search away.